DOCSLIB.ORG

Case M.8851 – BASF / BAYER DIVESTMENT BUSINESS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Case M.8851 – BASF / BAYER DIVESTMENT BUSINESS EUROPEAN COMMISSION DG Competition Case M.8851 – BASF / BAYER DIVESTMENT BUSINESS Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Decision on the implementation of the commitments - Purchaser approval Date: 07/11/2018 EUROPEAN COMMISSION Brussels, 07.11.2018 C(2018) 7488 final PUBLIC VERSION In the published version of this decision, some information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a general description. To the notifying party Dear Sir/Madam, Subject: Case M.8851 – BASF / Bayer Divestment Business Approval of Syngenta Crop Protection AG as purchaser of the [NSH line of research 1 remedy package], following your letter of 13 September 2018 and the Trustee’s opinion of 18 October 2018 FACTS AND PROCEDURE 1. By decision of 30 April 2018 (the "Decision") pursuant to Article 6(1)(b) in conjunction with Article 6(2) of Council Regulation (EC) No 139/2004 of 20 January 2004 on the control of concentrations between undertakings1 (the "Merger Regulation"), the Commission declared the acquisition of assets of Bayer Aktiengesellschaft (the "Bayer Divestment Business") by BASF SE ("BASF") compatible with the internal market subject to full compliance with the commitments submitted by BASF, which were annexed to the Decision (the "Commitments"). 2. In particular, pursuant to the Decision, the Commitments provide that in order to address the serious doubts raised by the combination of BASF's and the Bayer Divestment Business' activities in certain nematicide markets as well as in weed management innovation, BASF would divest (i) its Trunemco nematicide (the "Trunemco Assets") as well as, separately, (ii) a package of data and intellectual 1 OJ L 24, 29.01.2004, p. 1. With effect from 1 December 2009, the Treaty on the Functioning of the European Union ("TFEU") has introduced certain changes such as the replacement of "Community" by "Union" and "common market" by "internal market". The terminology of the TFEU will be used throughout this decision. Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË Tel: +32 229-91111. Fax: +32 229-64301. E-mail: [email protected] property rights relating to [mode of action 1] class herbicide chemistry type [mode of action 1] inhibitors, as well as a material transfer agreement and an option to a non-exclusive development and commercial licence regarding BASF’s [mode of action 1] which would permit the Purchaser to develop a corresponding [mode of action 1] HT trait in […]. Only the commitment to divest the [NSH line of research 1 remedy package] is concerned by this decision. 3. Against this background, by letter of 27 August 2018, as revised on 13 September 2018, BASF informed the Commission of its intention of selling the [NSH line of research 1 remedy package] to Syngenta Crop Protection AG ("Syngenta" or the "Proposed Purchaser") (hereinafter the "Transaction") and asked the Commission to approve Syngenta as purchaser of the [NSH line of research 1 remedy package]. BASF also submitted the transaction documents signed on 22 August 2018 bringing about the Transaction, namely: (i) […], (ii) […] and (iii) […] (together the "Transaction Agreements"). 4. On 18 October 2018, the monitoring trustee supervising the implementation of the Commitments, Mazars (the "Trustee"), separately submitted an assessment of Syngenta’s suitability as a purchaser (the "Reasoned Opinion"). In particular, the Trustee indicated that Syngenta fulfils the criteria of the purchaser requirements in paragraph 19 of the Commitments. In this assessment, the Trustee also indicated that, on the basis of the Transaction Agreements, the [NSH line of research 1 remedy package] would be sold in a manner consistent with the Commitments. ASSESSMENT OF THE PROPOSAL Legal framework 5. Pursuant to paragraph 20 of the Commitments, the Commission has to verify that the Proposed Purchaser fulfils the purchaser criteria and that the [NSH line of research 1 remedy package] is being sold in a manner consistent with the Commitments. 6. According to paragraph 19 of the Commitments, in its assessment of the Proposed Purchaser, the Commission should ensure in particular that: a. The purchaser is independent from and unconnected to each of BASF and Bayer and their affiliated undertakings. b. The purchaser has the financial resources, proven expertise and incentives to maintain and develop the [NSH line of research 1 remedy package] as a viable and active competitive force in competition with BASF and other competitors. In particular, the purchaser should have the necessary research and development organisation, trait stacking capabilities, registration capabilities and international reach to be able to develop and, if successful, launch a [mode of action 1] inhibitor that is the subject of the [NSH line of research 1 remedy package]. c. The acquisition of the [NSH line of research 1 remedy package] by the purchaser must neither be likely to create, in light of the information available to the Commission, prima facie competition concerns nor give rise to a risk that the implementation of the Commitments will be delayed. In particular, the purchaser must reasonably be expected to obtain all necessary approvals from 2 the relevant regulatory authorities for the acquisition of the [NSH line of research 1 remedy package]. Description of the Proposed Purchaser 7. Syngenta is a Swiss company active on a vertically-integrated basis in the research, development, manufacture and marketing of a wide range of crop protection products and seeds. 8. With global sales of approximately EUR 11.2 billion, Syngenta is one of the largest agricultural company worldwide. 9. Since May 2017, the ultimate owner of Syngenta is China National Chemical Corporation (“ChemChina”), a Chinese chemical corporation. Independence from each of BASF and Bayer 10. Pursuant to paragraph 19 (a) of the Commitments, in order to be approved by the Commission, a suitable purchaser must be independent from and unconnected to each of BASF and Bayer and their affiliated undertakings. 11. According to the information provided by BASF and the Trustee, there are no cross-shareholdings or common shareholdings between either of BASF or Bayer and Syngenta, and Syngenta does not share any executive and non-executive directors with BASF or Bayer.2 12. Although there are some joint-ventures in which either of BASF or Bayer and Syngenta participate, the Trustee concluded that these links are not material, are common in the industry and do not to affect Syngenta’s independence.3 13. Syngenta can therefore be considered to be independent from and unconnected to each of BASF and Bayer in terms of ownership and investments. 14. Moreover, the Trustee considers that pre-existing commercial relationships or collaborations in place between either of BASF or Bayer and Syngenta4 should not impede Syngenta's independence from each of BASF and Bayer because they are not material to Syngenta and have been concluded in line with industry practice.5 15. On the basis of the information provided by BASF and taking into account the Reasoned Opinion submitted by the Trustee, the Commission concludes that Syngenta is, and will continue to be post-Transaction, independent and unconnected to each of BASF and Bayer and their respective affiliated undertakings. Financial resources, proven expertise and incentive to maintain and develop the Divested Business as a viable and active competitor 16. Pursuant to paragraph 19 (b) of the Commitments, in order to be approved by the Commission, a suitable purchaser must have the financial resources, proven 2 Reasoned Opinion, paragraphs 6(a), 6(c), 114 and 137. 3 Reasoned Opinion, paragraphs 6(a), 6(b) and 131. 4 Such agreements include […] and others (Reasoned Opinion, paragraphs 160-326). 5 Reasoned Opinion, paragraphs 6(d), 331 and 338. 3 expertise and the incentives to maintain and develop the [NSH line of research 1 remedy package] as a viable and active competitive force in competition with BASF and other competitors. In particular, the purchaser must have the necessary research and development organisation, trait stacking capabilities, registration capabilities and international reach to be able to develop and, if successful, launch a [mode of action 1] inhibitor that is the subject of the [NSH line of research 1 remedy package]. 17. Syngenta has significant financial resources. In 2017, it achieved total sales of approximately 11.2 billion with a gross profit of EUR 5.45 billion. This compares to a purchase price of […] plus a licence fee for the [NSH line of research 1 remedy package], and a royalty payment for the [mode of action 1] Gene Licence. 18. In terms of proven expertise, Syngenta is an established crop protection player with a long history and extensive expertise, notably in herbicide research and innovation, including in relation to [mode of action 1] inhibitors. The Trustee considers that Syngenta will be able to integrate the [NSH line of research 1 remedy package] within its existing portfolio. 19. In particular, the Trustee considers that Syngenta has the necessary research and development organisation, trait stacking capabilities, registration capabilities and international reach
Load more

Recommended publications
  • Allianz Sustainable Investin G Report 2019
    Active is: Securing a brighter future Sustainable Investing Report 2019 Value. Shared. Lorem ipsum Contents Highlights 4 Advancing ESG integration 5 Expanding our sustainable investing offering 6 Integrating ESG in Fixed Income Active stewardship 8 Presenting a viewpoint: active engagement at AllianzGI 11 Engagement for work: an external perspective 12 Proxy voting The role of sustainable investing 14 Financing the transition: funding the low-carbon economy 17 Case study on carbon management: a guest contribution by the CEO of BASF SE 18 Impact investing and the UN's sustainability goals Insights 20 ESG and your portfolio: how do ESG factors impact portfolio performance? 22 Demand for ESG investments is growing: investors need guidance to turn interest to action 24 A new regulatory environment: the European Commission’s action plan for financing sustainable growth Client voices 26 Real results: ESG in action Environmental matters 30 Sea Cleaners: it‘s time to act 32 Becoming more eco-friendly 34 Active is: Fostering a low-carbon economy Allianz Global Investors twitter.com/AllianzGI_VIEW 2 Active is: Securing a brighter future The investment industry appears to be reaching a tipping point, where sustainable investing is no longer seen as a trend but rather as an intrinsic part of the way we run – or at least are expected to run – money as asset managers. As an active investor with a long-term outlook, we consider sustainability issues intuitively in our investment decisions and engagement. For colleagues across AllianzGI, this is part of our firm’s DNA. However, we also consider these issues consciously and deliberately.
    [Show full text]
  • Controlling Pregnancy: Fred Lyman Adair and the Influence of Eugenics on the Development of Prenatal Care
    Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2019 Controlling Pregnancy: Fred Lyman Adair And The nflueI nce Of Eugenics On The evelopmeD nt Of Prenatal Care Florence Hsiao Follow this and additional works at: https://elischolar.library.yale.edu/ymtdl Recommended Citation Hsiao, Florence, "Controlling Pregnancy: Fred Lyman Adair And The nflueI nce Of Eugenics On The eD velopment Of Prenatal Care" (2019). Yale Medicine Thesis Digital Library. 3504. https://elischolar.library.yale.edu/ymtdl/3504 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. Controlling Pregnancy: Fred Lyman Adair and the Influence of Eugenics on the Development of Prenatal Care A Thesis Submitted to the Yale University School of Medicine In Partial Fulfillment of the Requirements for the Degree of Doctor of Medicine By Florence Hsiao Class of 2019 Abstract This thesis examines the development of prenatal care in the United States in the early 1900s by focusing on the life and career of Fred Lyman Adair who, as an obstetrician and eugenicist, played a significant role in shaping prenatal care into what it is today. Although prenatal care was a product of infant welfare activists and public health officials, obstetricians like Adair who struggled to establish obstetrics as a legitimate specialty, saw an opportunity in prenatal care to pathologize pregnancy and elevate their specialty.
    [Show full text]
  • PDF Viewing Archiving 300
    I.C.FARBEN" INDUSTRIE AKTIEN" GESELLSCHAFT FRANKFURT (MAIN) 1 9 3 8 I. G. Farbenindustrie Aktiengesellschaft Frankfurt am Main Bericht des Vorstands und des Aufsichtsrats und Jahresabschluß für das Geschäftsjahr 1938. VORSTAN Geheimer Kommerzienrat Dr. HERMANN SCHMITZ, Ludwigshafen a. Rh./Heidelberg, Vorsitzer, Dr. FRITZ GAJEWSKI, Leipzig, Professor Dr. HEINRICH HäRLEIN, Wuppertal-Elberfeld, Dr. AUGUST v. KNIERIEM, Mannheim, Zentralausschuß Dr. CARL KRAUCH, Heidelberg-Schlierbach, Dr. FRITZ TER MEER, Kronberg (Taunus), Dr. CHRISTIAN SCHNEIDER, Leuna, Dr. GEORG von SCHNITZLER, Frankfurt (Main), Dr. OTTO AMBROS, Ludwigshafen a. Rh., Dr. MAX BRÜGGEMANN, Leverkusen-Wiesdorf, Dr. ERNST BÜRGIN, Bitterfeld, Dr. HEINRICH BÜTEFISCH, Leuna, Ministerialrat a. D. Dr. BERNHARD BUHL, Frankfurt (Main), PAUL HAEFLIGER, Frankfurt (Main), Dr. MAX JLGNER, Berlin-Steglitz, Dr. CONSTANTIN JACOBI, Frankfurt (Main), Dipl. Ing. FRIEDRICH JÄHNE, Frankfurt (Main), Dr. HANS KÜHNE, Leverkusen-Wiesdorf, Professor Dr. CARL LUDWIG LAUTENSCHLÄGER, Frankfurt (Main), Generalkonsul WILHELM RUDOLF MANN, Leverkusen-Wiesdorf. Dr. HEINRICH OSTER, Berlin-Charlottenburg, Kommerzialrat WILHELM OTTO, Berlin-Zehlendorf-West, Dr. OTTO SCHARF, Halle (Saale), Kommerzienrat HERMANN WAIBEL, Wiesbaden, Dr. HANS WALTHER, Frankfurt (Main), EDUARD WEBER-ANDREAE, Frankfurt (Main), Dr. CARL WURSTER, Ludwigshafen a. Rh. Im Geschäftsjahr oder nachher ausgeschieden: Kommerzienrat Dr. LUDWIG HERMANN, Frankfurt (Main) t 31. 5. 1938. AUFSICHTSRAT. Geheimer Kommerzienrat Professor Dr. CARL BOSCH, Heidelberg, Vorsitzer, Dr. WALTHER vom RATH, Kronberg (Taunus), stellvertretender Vorsitzer, Dr. WILHELM FERDINAND KALLE, Tutzing (Oberbayern), stellvertretender Vorsitzer, Dr. AXEL AUBERT, Oslo, Dr. RICHARD BAYER, Haus Falkenberg, Trills über Wuppertal-Vohwinkel, W ALDEMAR von BÖTTINGER, Landwirt, Schloß Arensdorf i. d. Neumark, Dr. WALTER von BRÜNING, Polizeipräsident a. D., Semper a. Rügen, Kommerzienrat LOTHAR BRUNCK, Kirchheimbolanden (Pfalz), Dr. CARL LUDWIG DUISBERG, Berlin-Zehlendorf-MiUe, Kommerzienrat Dr.
    [Show full text]
  • An Overview: Innovation in Plant Breeding
    An Overview: Innovation in Plant Breeding Modern plant breeding blends traditional ways of developing crops with the latest in science and technology to achieve improved crops – enabling more choices for both farmers and consumers, and producing crops that can better cope with evolving pests, diseases and a changing climate. The Basics What: The simplest definition of plant breeding is crossing two plants Most of the fruits, vegetables, and to produce offspring that share the best characteristics of the two grains that we eat today are the parent plants. Breeders make crosses then select which offspring to advance in the pipeline based on their desired characteristics. result of generations of plant breeding. About 5,000 years ago, Why: Even the earliest farmers understood that, in order to survive, watermelons were only they needed plant varieties specifically adapted to their environmental conditions and cultivated to produce the best foods to nourish their 2 inches in diameter livestock and communities. and had a bitter taste, vastly How: Through generations of research and discovery, plant breeding has advanced beyond selecting a parent plant simply based on its different from appearance. It now includes an in-depth understanding of plants’ the large, genetic makeup, enabling breeders to better predict which plants will sweet-tasting have the highest probability of success in the field and the grocery fruit we enjoy store before making a cross. today. The Background The earliest farmers were plant breeders who understood the value of identifying crops that showed beneficial characteristics to plant in future seasons. Later, they learned they could cross two plants to develop an even better plant.
    [Show full text]
  • The Debate on the Golden Rice and Its Background
    The Debate on the Golden Rice and its Background A Literature Review Klaus Ammann, [email protected] Dedicated to the inventor and relentless promoter of Golden Rice, Ingo Potrykus Judge GM crops on their properties, not the technique used to make them – and we can start saving lives Editorial help: Vivian Moses, Patrick and Michael Moore 20140615 references numbered with full text links Millions of children die worldwide every year, an untenable situation that is still worsening which needs immediate correction. According to the World Health Organization (1), an estimated 250 million preschool children are vitamin A deficient (= VAD) and it is likely that in VAD areas a substantial proportion of pregnant women are also affected in 2013. Earlier reports (2) make evident that the problems are still growing: (in 2004: 140 million preschool children and more than 7 million pregnant women were suffering from VAD) 2 Preface It is not the intention of the author for this literature compilation on Golden Rice to replace the two websites www.goldenrice.org and www.allowgoldenricenow.org, they contain major information pieces, are well organized and specific information is easy to access. Rather it is the aim here to pull together a set of publications related to the background of the Golden Rice debate. We often are confronted with all kinds of determined opinions about the Golden Rice, Bio-Fortification, Transgenic Plants, Traditional and Organic Agriculture etc. and it is the purpose of this summary to shed light to the background of opinions pro and contra the Golden Rice – on how and why those opinions grow and how they are unfortunately melting down into simplistic slogans.
    [Show full text]
  • View Presentation
    Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva1 Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda
    [Show full text]
  • We Drive Sustainable Solutions
    We drive sustainable solutions Dr. Tim Balensiefer Investor Relations Allianz Investor Day Frankfurt, June 5, 2018 1 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements. These statements are based on current estimates and projections of the Board of Executive Directors and currently available information. Forward-looking statements are not guarantees of the future developments and results outlined therein. These are dependent on a number of factors; they involve various risks and uncertainties; and they are based on assumptions that may not prove to be accurate. Such risk factors include those discussed in the Opportunities and Risks Report from page 111 to 118 of the BASF Report 2017. BASF does not assume any obligation to update the forward-looking statements contained in this presentation above and beyond the legal requirements. 2 Sustainability along the value chain Our commitments Suppliers BASF Customers We source We produce safely We drive responsibly for people and sustainable the environment solutions We produce efficiently We value people and treat them with respect 3 Sustainable development UN Sustainable Development Goals and material aspects provide strategic frame BASF material Energy Food Water Resources Responsible Products Partnering Employment aspects and and eco- production and and employ- BASF particularly climate systems solutions ability contributes to: 1 No poverty 2 No hunger 3 Good health 4 Quality education 5 Gender equality 6 Clean water and sanitation 7
    [Show full text]
  • Bayer Cropscience Contaminates Our Rice
    Bayer e CropScience contaminates our rice greenpeace.org Campaigning for Sustainable Agricultur Greenpeace is an independent global campaigning organisation that acts to change attitudes and behaviour, to protect and conserve the environment and to promote peace. Contents A Contamination Nightmare 3 US Export markets impacted by GE contamination 4 Key dates in the LL rice scandals 5 The situation now 6 LL601 and other Bayer GE rice varieties 7 Should consumers be worried about eating LL rice? 7 Contamination threats 8 Bayer CropScience 9 Rice facts 9 Securing a Healthy Industry - Conclusion and Demands 10 End Notes 11 For more information contact: [email protected] JN 085 Published in October 2007 by Greenpeace International Ottho Heldringstraat 5 1066 AZ Amsterdam The Netherlands Tel: +31 20 7182000 Fax: +31 20 5148151 greenpeace.org Cover image: ©Greenpeace/Novis Bayer CropScience contaminates our rice The following is a summary of events Japan and Korea imposed equally strict testing requirements, surrounding one of the worst cases of genetic followed some months later by the Philippines when engineering contamination of food in history Greenpeace revealed contamination there. Russia and Bulgaria imposed bans on US rice and Mexico, Iraq and and one of the most damaging events in the Canada imposed test and certification requirements on history of the US rice industry. imports. The United Arab Emirates required a GE free guarantee. (5) The devastation has been caused by the multinational company Bayer CropScience - which maintains that the contamination As of July 2007, Greenpeace has identified 30 countries wasn't their fault - it was an 'act of God'.
    [Show full text]
  • Agribusiness and Antitrust: the Bayer-Monsanto Merger, Its Legality, and Its Effect on the United States and European Union
    The Global Business Law Review Volume 7 Issue 1 Article 9 7-1-2018 Agribusiness and Antitrust: The Bayer-Monsanto Merger, Its Legality, and Its Effect on the United States and European Union Aleah Douglas Cleveland-Marshall College of Law Follow this and additional works at: https://engagedscholarship.csuohio.edu/gblr Part of the Antitrust and Trade Regulation Commons, and the Business Organizations Law Commons How does access to this work benefit ou?y Let us know! Recommended Citation Aleah Douglas, Agribusiness and Antitrust: The Bayer-Monsanto Merger, Its Legality, and Its Effect on the United States and European Union, 7 Global Bus. L. Rev. 156 (2018) available at https://engagedscholarship.csuohio.edu/gblr/vol7/iss1/9 This Note is brought to you for free and open access by the Journals at EngagedScholarship@CSU. It has been accepted for inclusion in The Global Business Law Review by an authorized editor of EngagedScholarship@CSU. For more information, please contact [email protected]. AGRIBUSINESS AND ANTITRUST: THE BAYER-MONSANTO MERGER, ITS LEGALITY, AND ITS EFFECT ON THE UNITED STATES AND EUROPEAN UNION ALEAH DOUGLAS I. INTRODUCTION……………………………………………………………………... 157 II. BACKGROUND…………………………………………………………………….....158 A. A Review of the Bayer-Monsanto Merger………………………….…………... 158 B. United States Antitrust Laws…………………………………………………… 161 1. The Applicable Laws……………………………………………………. 161 2. Problems and Antitrust Violations……………………………………… 166 3. American Agribusiness…………………………………………………. 167 C. European Union Antitrust Laws……………………………………………….. 172 1. The European Union……………………………………………………. 172 2. The Applicable Laws………………………………….………………… 172 3. Problems and Antitrust Violations……………………….………....…... 174 4. European Union Agribusiness…………….…………………………….. 176 D. Illegality and Detriment …………………………………….…………………. 178 III. CONCLUSION……………………………………………………………………....... 180 ABSTRACT This note examines the current and historical antitrust laws of the United States and the European Union as they relate to the currently pending merger between Bayer and Monsanto.
    [Show full text]
  • 3 Corporate Governance Report
    Chapter 3 pages 148–184 Corporate Governance Report 149 Compensation Report 162 Compliance 157 Report of the Supervisory Board 176 Management and Supervisory Boards 159 Declaration of Conformity Pursuant to ­­ Board of Executive Directors 159 Section 161 AktG 183 Supervisory Board 160 Declaration of Corporate Governance 184 3Corporate Governance About This Report 1 To Our Shareholders 2 Management’s Report 3 Corporate Governance 4 Consolidated Financial Statements 5 Overviews Corporate Governance Report Corporate Governance Super visory Board; and the shareholders’ rights of co-administra- the establishment of appropriate systems for control, compliance tion and supervision at the Annual Shareholders’ Meeting. and risk management as well as establishing a company-wide Report compliance culture with undisputed standards. Direction and management by the Board of Executive Directors Decisions that are reserved for the Board as a whole by law, through Corporate governance refers to the entire system for the Board of Executive Directors’ Rules of Procedure or through managing and supervising a company. This includes its ▪ Board of Executive Directors strictly separate from the resolutions adopted by the Board, are made at regularly held Board organization, values, corporate principles and guidelines Supervisory Board meetings called by the Chairman of the Board of Executive Directors. as well as internal and external control and monitoring ▪ Responsible for company management Board decisions are based on detailed information and analyzes mechanisms. Effective and transparent corporate gover- ▪ Sets corporate goals and strategic direction provided by the business areas and specialist units, and, if deemed nance ensures that BASF is managed and supervised necessary, by external consultants. Board decisions can generally responsibly with a focus on value creation.
    [Show full text]
  • Euro Stoxx® 50 Ex Banks Index
    BLUE-CHIP INDICES 1 EURO STOXX® 50 EX BANKS INDEX Index description Key facts STOXX calculates several ex region, ex country and ex sector indices. This » Transparent and rules-based methodology means that from the main index a specific region, country or sector is » Buffer rule aims to reduce turnover excluded. The sector classification is based on ICB Classification (www.icbenchmark.com.) Some examples: » Weighted by free-float market cap a) Blue-chip ex sector: the EURO STOXX 50 ex Financial Index excludes all companies assigned to the ICB code 8000 b) Benchmark ex region: the STOXX Global 1800 ex Europe Index excludes all companies from Europe c) Benchmark ex country: the STOXX Europe 600 ex UK Index excludes companies from the United Kingdom d) Size ex sector: the STOXX Europe Large 200 ex Banks Index excludes all companies assigned to the ICB code 8300 Risk and return figures1 Index returns Return (%) Annualized return (%) Last month YTD 1Y 3Y 5Y Last month YTD 1Y 3Y 5Y EURO STOXX 50 ex Banks Index 0.1 3.5 1.9 29.1 49.4 N/A N/A 1.9 9.0 8.5 EURO STOXX 50 Index 0.3 0.2 -2.1 22.1 40.3 N/A N/A -2.1 7.0 7.1 Index volatility and risk Annualized volatility (%) Annualized Sharpe ratio2 EURO STOXX 50 ex Banks Index 11.5 12.9 12.1 15.6 17.0 N/A N/A 0.3 0.6 0.5 EURO STOXX 50 Index 11.3 12.9 12.0 16.6 17.9 N/A N/A -0.1 0.5 0.4 Index to benchmark Correlation Tracking error (%) EURO STOXX 50 ex Banks Index 1.0 1.0 1.0 1.0 1.0 2.4 1.9 2.0 2.9 2.7 Index to benchmark Beta Annualized information ratio EURO STOXX 50 ex Banks Index 1.0 1.0 1.0 0.9 0.9 -1.3 2.3 2.0 0.6 0.4 Performance and annual returns3 1 For information on data calculation, please refer to STOXX calculation reference guide.
    [Show full text]
  • RWE, BASF and Linde
    News release Herrn Peter Karl Wettstein BASF SE WLL/SD D 211 - Raum 205 RWE, BASF and Linde: Breakthrough in capturing carbon from flue gas of coal-fired power plants New technology saves 20 percent on energy input and clearly reduces solvent consumption Key to climate-compatible coal-based power generation Essen/Cologne/Ludwigshafen, 03. September 2010 Since 2009 RWE, Linde and BASF have been testing a new technology for separating carbon dioxide (CO2) from flue gas in a pilot plant at RWE’s Niederaussem power station near Cologne. The results of the practical test are now available: Compared to processes commonly run today, the innovative technology that captures CO2 by means of new chemical solvents can reduce energy input by about 20 percent. The new solvents also feature clearly superior oxygen stability, which reduces solvent consumption significantly. “We are pleased with this breakthrough, which we have achieved by cooperating closely with BASF and Linde. By enhancing efficiency and accordingly reducing costs, we have created a critical success factor for carbon capture technology, which in our view is key to climate- compatible power generation from coal,” underlines Dr. Johannes Heithoff, Vice President, Research and Development, RWE Power. “The practical tests met all of the expectations we had after lab-testing the new solvent. This paves the way for scaling up the process to large power plants,” says Dr. Andreas Northemann, Business Manager, Global Gas Treatment, BASF Intermediates division. “We are very satisfied with the results of the practical tests, too,” says Dr. Aldo Belloni, Member of the Executive Board of Linde AG.
    [Show full text]